Pharmaceuticals company Marksans Pharma announced Q3FY26 results Operating revenue stood at Rs 754.4 crore, up by 10.6% YoY, attributed to strong traction in the US and UK markets, supported by robust momentum from new product launches and market share gains. Gross profit stood at Rs 438.2 crore, up by 14.3% YoY, with gross margin of 58.1%. EBITDA stood at Rs 160.7 crore; EBITDA margin at 21.3%, expanded 217 bps YoY. EPS was Rs 2.5. Mark Saldanha, Managing Director, said: “We delivered a stable and resilient performance in Q3FY26, with operating revenue growing 10.6% YoY, supported by steady execution across key markets and improved seasonal demand. Margins expanded sequentially, driven by soft raw material costs, favorable currency movements, and an improving product mix, while EBITDA growth reflected operating leverage. During the quarter, we took measured steps to strengthen our global footprint through new subsidiaries in Europe and Canada, positioning the Company for long-term growth in regulated markets. We remain disciplined, executionfocused, and committed to delivering sustainable growth and long-term shareholder value.” Result PDF